# Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig

> **NCT07636863** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 200 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Nivolumab
- **COMBINATION_PRODUCT:** Subcutaneous nivolumab combined with hyaluronidase

## Key facts

- **NCT ID:** NCT07636863
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-08-21
- **Primary completion:** 2025-12-22
- **Final completion:** 2026-03-27
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2026-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07636863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07636863, "Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07636863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*